Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Damora Therapeutics, Inc.

CIK 1800315 DMRA·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Auditor change 8-K
  2. Finance chief departure 8-K +14d
Refine

Finance chief departure high Filing comparison

Damora Therapeutics, Inc.'s Chief Financial Officer departed with no named successor

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
high
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Auditor change SEC item code

Damora Therapeutics, Inc. dismissed its auditor and engaged EY

The company dismissed the auditor. not stated → EY

Evidence
Direction
dismissed
Direction label
The company dismissed the auditor
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Severity
normal
Source
SEC 8-K item code
Successor auditor
EY
Successor tier
big_four
Why
The company's independent registered accounting firm changed.

Source filing ↗